Biotinylated SARS-CoV-2 Spike S1 (T19R, G142D, EF156-157del, R158G, L452R, T478K, D614G, P681R), His,Avitag™

Immobilized Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgG1 (Cat. No. S1N-M122) at 1 ug/mL (100 uL/well) can bind Biotinylated SARS-CoV-2 Spike S1, His, Avitag (Cat. No. S1N-C82E5) with a linear range of 0.2-6 ng/mL (QC tested).

PBS, pH7.4

It's been reported that SARS-CoV-2 can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Val 16 - Arg 685

78.4 kDa

Biotinylated SARS-CoV-2 Spike S1, His, Avitag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

Biotinylated SARS-CoV-2 Spike S1, His, Avitag (S1N-C82E5) is expressed from human 293 cells (HEK293). It contains AA Val 16 - Arg 685 (Accession # QHD43416.1). The mutations (T19R, G142D, EF156-157del, R158G, L452R, T478K, D614G, P681R) were identified in the SARS-CoV-2 Delta variant (Pango lineage: B.1.617.2; other names: 21A/S:478K).